MultiCell Technologies Signs Worldwide Exclusive License Agreement with Corning Incorporated
News Oct 11, 2007
MultiCell Technologies, Inc. entered into a worldwide exclusive license and technology purchase agreement with Corning Incorporated of Corning, NY concerning the Company's Fa2N-4 immortalized adult human liver cell lines.
Corning paid MultiCell a license fee, and has agreed to purchase certain inventory and equipment related to MultiCell's Fa2N-4 cell line business, hire certain MultiCell scientific personnel, and pay for access to MultiCell's laboratories during transfer of the Fa2N-4 cell lines to Corning.
MultiCell will retain and continue to support all of its existing licensees, including Pfizer, Bristol-Myers Squibb, and Eisai. MultiCell retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays.
MultiCell also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to produce therapeutic proteins using the Company's BioFactories™ technology, to identify drug targets and for other applications related to the Company's internal drug development programs.
"We are pleased to partner with Corning in the drug discovery assay tools, ADME/Tox and biomarker segments. MultiCell's focus is on using our therapeutic antibody and Toll-like receptor (TLR) technologies to develop new drug candidates, and to advance our lead drug candidate, MCT-125, for the treatment of primary MS-related fatigue," said Jerry Newmin, Chairman of the Board of MultiCell Technologies.
Chemists Design More Efficient Microreactor Using 3D PrintingNews
Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE